$30.170
-0.809 (-2.68%)At close
AVBP News
AVBP Events
ArriVent CEO Reveals Potential of Firmonertinib as First-Line Treatment Option
"Our FURVENT and ALPACCA global pivotal trials have the potential to establish firmonertinib as a first-line treatment option for uncommon EGFR mutations in non-small cell lung cancer (NSCLC), addressing a significant unmet need for patients who remain underserved by current therapies," said Bing Yao, CEO of ArriVent. "In parallel, we continue to build a differentiated ADC portfolio, with ARR-217 advancing into dose optimization and ARR-002 advancing in clinical development. We look forward to presenting pivotal topline data from our global FURVENT study for firmonertinib and initial Phase 1 data for ARR-217."
ArriVent CEO Reveals Firmonertinib Clinical Progress
"Our two ongoing pivotal firmonertinib trials in uncommon EGFR-mutant non-small cell lung cancer continue to advance, with topline monotherapy data for frontline EGFR exon 20 insertion mutations expected in mid-2026 and our global Phase 3 pivotal ALPACCA study continuing to enroll patients globally," said Bing Yao, CEO of ArriVent. "At American Association for Cancer Research, we presented preclinical data highlighting the unique structural features of firmonertinib that improve binding and enhance activity against EGFR mutant proteins, further strengthening confidence in the broad activity of firmonertinib in EGFR-mutant NSCLC."
ArriVent BioPharma Receives FDA Clearance for ARR-002 IND
ArriVent BioPharma announced clearance of an investigational new drug application by the FDA for ARR-002, a MUC16/NaPi2b targeting tetravalent antibody-drug conjugate with an initial focus in ovarian and endometrial cancers and broader therapeutic potential across solid tumors.
ArriVent Doses First Patient in Global Phase 3 ALPACCA Study for Firmonertinib
ArriVent BioPharma announced that the first patient has been dosed in the global pivotal Phase 3 ALPACCA study evaluating firmonertinib monotherapy for first-line treatment of EGFR PACC mutant non-small cell lung cancer, NSCLC. "Initiation of our pivotal Phase 3 ALPACCA trial marks an important milestone in our strategy to expand the global reach of firmonertinib," said Bing Yao, Ph.D., Chairman and Chief Executive Officer of ArriVent. "Patients with EGFR PACC mutant NSCLC currently have limited treatment options and represent a clear unmet medical need. With a well-characterized safety profile and broad clinical systemic and central nervous system activity in patients, we believe firmonertinib is strongly positioned to bring meaningful innovation to NSCLC patients with PACC mutations and the potential to become a cornerstone therapy across the EGFR mutant spectrum."
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。